Testosterone not associated with an increase in incident CV events: Study

Written By :  Dr. Shravani Dali
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2021-09-22 16:00 GMT   |   Update On 2021-09-22 15:58 GMT

Testosterone use was not associated with an increase in incident CV events in this patient population, suggests a study published in the Journal of the American Heart Association. Testosterone treatment is common in men, although risks for major cardiovascular events are unclear. A group of researchers from U.S.A conducted in US male veterans, aged ≥40 years, with low...

Login or Register to read the full article

Testosterone use was not associated with an increase in incident CV events in this patient population, suggests a study published in the Journal of the American Heart Association.

Testosterone treatment is common in men, although risks for major cardiovascular events are unclear.

A group of researchers from U.S.A conducted in US male veterans, aged ≥40 years, with low serum testosterone and multiple medical comorbidities and without a history of myocardial infarction, stroke, venous thromboembolism, prostate cancer, or testosterone treatment in the prior year.

For the primary outcome, we examined if testosterone treatment was associated with a composite cardiovascular outcome (incident myocardial infarction, ischemic stroke, or venous thromboembolism).

Testosterone use was modelled as intramuscular or transdermal and as current use, former use, and no use. Current testosterone users were compared with former users to reduce confounding by indication.

The results of the study are as follows:

· The cohort consisted of 204 857 men with a mean (SD) age of 60.9 (9.9) years and 4.7 (3.5) chronic medical conditions.

· During follow‐up of 4.3 (2.8) years, 12 645 composite cardiovascular events occurred.

· In adjusted Cox regression analyses, current use of transdermal testosterone was not associated with risk for the composite cardiovascular outcome in those without prevalent cardiovascular disease, and in those with prevalent cardiovascular disease was associated with lower risk.

· In similar analyses, current use of intramuscular testosterone was not associated with risk for the composite cardiovascular outcome in men without or with prevalent cardiovascular disease.

The researchers concluded that in a large cohort of men without a history of myocardial infarction, stroke, or venous thromboembolism, testosterone treatment was not associated with increased risk for incident composite cardiovascular events.

Reference:

Association Between Testosterone Treatment and Risk of Incident Cardiovascular Events Among US Male Veterans with Low Testosterone Levels and Multiple Medical Comorbidities by Shores M et. al published in the Journal of the American Heart Association.

https://doi.org/10.1161/JAHA.120.020562


Tags:    
Article Source : Journal of the American Heart Association

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News